ProFem

Name

ProFem

Legal name

Profem GmbH

Website

https://profem.at

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceutical Drug Development

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Gynecological drug development
• Women's health pharmaceuticals
• Antifungal drug therapy
• Biofilm infection treatment
• Clinical drug development

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Licensing / Royalties: ProFem plans to generate revenue through worldwide out-licensing of Candiplus® to pharmaceutical industry partners for further development, approval, and commercialization. Licensing/royalties will be the primary revenue stream once regulatory approvals (EU, USA) are obtained and the product is launched commercially.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

ProFem develops Candiplus®, a patent-protected combination drug for the local treatment of recurrent vulvovaginal candidiasis (RVVC), using a novel synergistic mechanism that blocks Candida adhesion and invasion, overcomes biofilm resistance, and normalizes the host-microorganism interaction. The product is the first-in-class treatment for chronic biofilm-associated vaginal fungal infections and is currently in the regulatory approval phase (EMA centralized procedure) with planned out-licensing to pharmaceutical partners for worldwide commercialization.

Product overview

ProFem is a Vienna-based pharmaceutical company founded in 2012, specializing in the clinical development of innovative drugs for women's health conditions. Its lead product is Candiplus®, a first-in-class, patent-protected combination drug for the local treatment of frequently recurring and chronic vaginal fungal infections (recurrent vulvovaginal candidiasis, RVVC). The product works through a novel synergistic mechanism that blocks Candida adhesion/invasion, overcomes biofilm resistance, and normalizes the host-microorganism interaction. Clinical trials for all phases through Phase III have been completed, with Phase IIb-3 showing significant advantages over standard therapies in cure rate and relapse prevention. The company is pursuing regulatory approval in the EU and USA, and is seeking licensing/cooperation partners from the pharmaceutical industry. ProFem also publishes a women's health blog (Blog) covering topics such as vaginal flora health, fungal infection prevention, and women's disease research awareness.

Differentiator

Problem solved

Functional benefit

Brands

• Candiplus®: Patent-protected drug for local treatment of frequently recurring vaginal fungal infections. First-in-class medication based on synergistic effects of active ingredient components targeting biofilm resistance mechanisms.

Products and services

• Candiplus® A patent-protected combination drug for the local treatment of frequently recurring vaginal fungal infections (recurrent vulvovaginal candidiasis, RVVC). Based on a novel synergistic mechanism of action that blocks adhesion and invasion, overcomes biofilm resistance, and normalizes the microorganism-host interaction — the first-in-class treatment for chronic RVVC.

Quantifiable outcome

• Phase IIb-III: Significantly improved primary cure rate vs approved therapies; significantly reduced relapse rate vs approved therapies
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Pharmaceutical Licensing/Cooperation Partners (unspecified)coreOEM/ Whitelabel/ Licensing PartnerProFem is actively seeking licensing or cooperation partners from the pharmaceutical industry for the further development, regulatory approval, and market launch of its flagship product Candiplus®. The company aims to out-license globally while it focuses on completing clinical development and regulatory processes in the EU and USA.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Organon: Organon is a global women's health-focused pharma company spun off from Merck in 2021. Comparable because Organon is a natural strategic acquirer / out-licensing partner for Candiplus® given its dedicated focus on gynecology, reproductive health, and underserved women's conditions.
• Theramex (Teva Women’s Health spinoff): Theramex is a global women's health specialty pharma focused on contraception, fertility, menopause, and gynecological conditions, owned by CVC and previously part of Teva. Comparable as a mid-sized women's health pure-play and a logical out-licensing / commercial partner for Candiplus® across Europe and emerging markets.
• Pfizer: Pfizer markets Diflucan (fluconazole), the systemic antifungal gold standard for VVC. Comparable as the dominant systemic incumbent in the same indication ProFem is targeting with a local therapy, and as a potential large-pharma out-licensing counterparty with significant women's health commercial infrastructure.
• Bayer: Bayer markets Canesten / Gyno-Canesten (clotrimazole), the leading OTC antifungal brand for VVC globally. Comparable because Bayer is the dominant commercial incumbent in the same therapeutic category ProFem targets, and is a likely candidate as a commercial partner given its women's health and consumer health footprint.
• Ferring Pharmaceuticals: Ferring is a private Swiss specialty pharma with a significant women's health and reproductive medicine portfolio (e.g., Endometrin, reproductive therapies). Comparable as a mid-sized women's health incumbent and a plausible out-licensing partner for Candiplus® in Europe and emerging markets.
• Gedeon Richter: Gedeon Richter is a Hungarian-headquartered pharma with a strong women's health franchise, including the recent acquisition of Mycovia (oteseconazole for RVVC). Directly relevant as a competitor in the same RVVC niche and as a potential in-licensing partner for Candiplus® given its demonstrated appetite in this category.

Others

• Glenmark Pharmaceuticals: Glenmark is a global generic and specialty pharma with a significant antifungal portfolio and women's health presence, particularly in India and emerging markets. Comparable as a potential regional out-licensing partner for Candiplus® in geographies where ProFem lacks its own commercial reach.

Emerging players

• Daré Bioscience: Daré Bioscience is a clinical-stage women's health specialty biotech with a portfolio across contraception, vaginal health, and gynecological conditions. Comparable as a similarly-sized, similarly-staged (clinical / pre-commercial) women's health biotech pursuing innovative therapies for underserved female conditions.

Direct peers

• Scynexis: Scynexis developed ibrexafungerp (Brexafemme), a novel antifungal approved by FDA for vulvovaginal candidiasis. Directly comparable in mechanism class (innovative antifungal for VVC/RVVC), regulatory pathway, and target prescriber base (gynecologists and women's health providers).
• Mycovia Pharmaceuticals (Gedeon Richter): Mycovia developed oteseconazole (VIVJOA), the first FDA-approved drug specifically for reducing recurrence of RVVC, and was acquired by Gedeon Richter. It is the most direct competitor to Candiplus® given the same patient population, same antifungal positioning, and same business model of out-licensing / commercializing an RVVC-specific therapy.

Market position

Strengths4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profem.workingforwomenshealth
• LinkedInlinkedin.com/company/profem-at
• Instagraminstagram.com/www.profem.at

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProFem